Voyager Therapeutics, Inc.
VYGR
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington'sā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.03
Price-3.20%
-$0.10
1Y
Price
Market Cap
$183.077m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-201.1%
EBITDA Margin-208.7%
Net Profit Margin-233.9%
Free Cash Flow Margin-201.1%
EBITDA Margin-208.7%
Net Profit Margin-233.9%
Free Cash Flow MarginRevenue
$36.494m
-60.9%
1y CAGR+127.4%
3y CAGR+97.9%
5y CAGREarnings
-$116.637m
-95.0%
1y CAGR+47.0%
3y CAGR+44.0%
5y CAGREPS
-$1.98
-91.1%
1y CAGR+38.8%
3y CAGR+36.8%
5y CAGRBook Value
$173.669m
$219.325m
Assets$45.656m
Liabilities$34.566m
DebtDebt to Assets
15.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$129.943m
-531.2%
1y CAGR-19.5%
3y CAGR+3.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company